HIMS
Not your average FDA meeting
Hims & Hers just got a little extra pep in its step. The FDA is planning an advisory panel meeting in July to review whether certain peptides should be eligible for compounding again, a shift that would revisit restrictions put in place back in 2023.
Why the market cares
For Hims, this isn’t just regulatory wallpaper. The company has leaned into peptide-based offerings, so any move that expands compounding eligibility could open the door to more products, more prescriptions, and potentially more revenue. In premarket trading, the stock jumped more than 10%, which is basically the market saying, “I’ll take the optionality, thanks.”
But don’t get too far ahead of the paperwork
This isn’t a done deal — it’s an advisory process that could keep simmering until early 2027. So while the headline is bullish, the real story is still a waiting game: the FDA is kicking the can down the road, just with a lot more science and a lot more lawyers.
Big picture
For investors, the takeaway is simple: Hims just got another regulatory tailwind story, and those can matter a lot when your growth narrative depends on product expansion. If the FDA opens the door, Hims could walk through it with a bigger catalog and a louder growth pitch.